0

Back to Validating Antibodies for IHC Including Parallel Testing
Validating Antibodies for IHC Including Parallel Testing

Validating Antibodies for IHC Including Parallel Testing

Release Date: Sep 2017

MOC: MK, PBL

Sheron C. Lear, HT(ASCP)HTL, QIHC
R & D, IHC Specialist & Histology Education, CPA Laboratory, Louisville, KY

 

Description:

Prior to use on a patient tissue, immunohistochemistry stains must be optimized for appropriate noise to signal ratio, sensitivity, and specificity of signal. This can be a simple procedure or a challenge. Several factors must be considered: pre-analytic, analytic, and post-analytic. Pre-analytic factors include warm and cold ischemia, fixation, processing, and microtomy. Analytic factors include IHC protocols, pretreatment or lack of pretreatment, tittering the antibody, deletion of endogenous substances, systems, chromogens, and enhancements such as copper to darken the reaction product. Post-analytic factors include interpretation and documentation. The regulations include validating lot to lot parallel testing, shipment to shipment, and maintaining records of this for inspection purposes. Additional testing is required when there is a change in clones, pretreatments, protocols, etc. Also discussed in this webcast will be control tissues and instrumentation used in IHC.


After attending this session, participants will be able to:

·         Review the steps necessary to validate a new antibody.

·        Perform lot to lot testing, shipment to shipment, and detection system testing.

·        Understand the regulations and why they are important.


Who should attend?  Practicing Pathologists, Residents, Doctoral Scientists, Pathologists' Assistants, Laboratory Managers, Bench Supervisors, Bench Technologists & Technicians, Histotechnologists, Students

  • List Price: $275.00 USD

Item Details:
Validating Antibodies for IHC Including Parallel Testing
Back to Validating Antibodies for IHC Including Parallel Testing

Bought This Bought That ...